Navigation Links
AVN944 in Medical Technology

Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial

GERMANTOWN, Md., June 13, 2007 /PRNewswire-FirstCall/ -- Avalon Pharmaceuticals, Inc. , today announced that it is will provide an update on the Phase I clinical trial of AVN944 in hematologic malignancies on Tuesday, June 19, 2007, after the close of the U.S. financial markets. The Company will a...

Avalon Pharmaceuticals to Present at the American Association for Cancer Research 2007 Annual Meeting

...valon Pharmaceuticals, Inc. , today announced that avn944 will be the subject of three poster presentations ...and in vivo experiments that reveal the effects of avn944 on blood vessel formation. The presentation will b...acific Time. Another poster that will discuss avn944 will be presented by the lab of Dr. Beverly Mitche...

Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial

...rly and refractory patients. Interim data indicate avn944 is well tolerated, has dose-dependent pharmacokine...ncouraged by the positive interim results from the avn944 trial," stated Michael Hamilton, M.D., Avalon Phar...tiate multiple Phase II studies." Background: avn944 is an oral small molecule drug that inhibits inosi...
AVN944 in other areas

Avalon Pharmaceuticals Initiates AVN944 Phase I Clinical Trial in ...

We believe that AVN944 has the potential to offer oncologists and cancer patients ... of the safety and tolerability of AVN944 in adult patients with advanced ...

Microsoft Word - 090705_Avalon

Drug Administration (FDA) for their lead candidate, AVN944 for treatment of cancer. ... AVN944 is an inhibitor of the enzyme inosine monophosphate ...

Avalon Updates The AVN944 Phase I Hematologic Malignancies Trial

Avalon Pharmaceuticals, Inc. (Nasdaq: AVRX), today announced that it is will provide an update on the Phase I clinical trial of AVN944 in hematologic malignancies on ...

FOR IMMEDIATE RELEASE Contacts: Avalon Pharmaceuticals, Inc. Noonan ...

AVN944 is an orally bioavailable inhibitor of inosine monophosphate dehydrogenase 1 and 2 ... of sensitivity and resistance to AVN944 ... benefit from AVN944. ...

Avalon Pharmaceuticals Announces the Activation of IND for AVN944 for ...

AVN944 is an oral, small molecule inhibitor of the enzyme inosine monophosphate ... AVN944 was in-licensed by Avalon from Vertex Pharmaceuticals Incorporated ...

Summary of AVALON PHARMACEUTICALS INC - Yahoo! Finance

... therapeutics, and the in-license and development of AVN944. ... AVN944 was in-licensed by us from Vertex in February 2005. Financial Operations Overview ...
Other Tags
(Date:7/9/2014)... The National Institute of Allergy and Infectious Diseases ... has launched an early-stage clinical trial of CRS3123, ... Clostridium difficile ( C. difficile ) infection. ... agent that inhibits C. difficile growth while sparing ... will enroll up to 30 healthy men and ...
(Date:7/9/2014)... poor printing on prescription labels handed out by ... errors in taking medication, according to new research ... National Institute for the Blind)., The study, published ... found that labels on prescription medications dispensed by ... for legibility. , By simply following recommended guidelines ...
(Date:7/9/2014)... A study published in the scientific journal ... Bonin, two researchers at Universit Laval, reveals that it ... method that involves rekindling pain so that it can ... means to alleviate chronic pain. , The researchers from ... universitaire en sant mentale de Qubec (IUSMQ) were inspired ...
(Date:7/8/2014)... and cardiovascular health as other healthy mature individuals, according ... Journal of Transplantation . The findings may provide some ... professionals caring for them. , Over the past two ... and older has become more common. Given the links ... removal of a kidney could make older donors vulnerable ...
(Date:7/8/2014)... A team of clinicians from Plymouth, UK, and Sydney, ... 10th July Australia) launched ACEmobile - a free-to-use app ... , ACEmobile is the first of its kind; an ... tool provides support through the whole process, meaning more ... out this type of assessment. Designed by clinicians for ...
Breaking Medicine News(10 mins):Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2Health News:Discovery of a new means to erase pain 2Health News:Study finds kidney donation safe for healthy older adults 2Health News:New app widens opportunities for dementia assessments 2Health News:New app widens opportunities for dementia assessments 3
(Date:7/9/2014)... can alleviate the symptoms of Alzheimer,s disease, ... and effectively scavenge amyloid beta peptide in ... reduced and eliminated Aβ deposition in an ... significantly improved behavioral and cognitive impairment. Dr. ... Hospital of China Medical University, China immunized ...
(Date:7/9/2014)... high levels of vitamin D in their blood are more ... Patients with the highest levels of vitamin D have half ... levels, the findings reveal. , The study is the first ... cancer patients after their diagnosis which includes that produced ... with their long term survival prospects. , The ...
(Date:7/9/2014)... first make a copy of its DNA, a fundamental step ... times a day in the human body. While scientists have ... to replicate DNAthe enzymes that unzip the double-stranded DNA and ... how the process works. , Now, researchers at Rockefeller University ... on at the "replication fork"the point where DNA is split ...
Breaking Biology News(10 mins):Rockefeller scientists first to reconstitute the DNA 'replication fork' 2Rockefeller scientists first to reconstitute the DNA 'replication fork' 3Rockefeller scientists first to reconstitute the DNA 'replication fork' 4
Other Contents